NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024 BusinessWire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on NBY
    NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
    6:38p ET March 25 '24 BusinessWire

    NovaBay(R) Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

    Date/Time:             Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT
         
    Pre-Registration:      Participants can pre-register for the conference call here:
         
        Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
         
    Dial In:               Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:
        833-816-1121 from within the U.S.
    

    The live webcast of the conference call also will be available on the Events section of the Company website. A replay of the call will be available beginning two hours after its completion through April 16, 2024 by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 1489846. The webcast will also be archived here.

    About NovaBay Pharmaceuticals, Inc:

    NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products. NovaBay's leading product Avenova(R) Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to consumers through online distribution channels such as Amazon.com. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne(R) brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase(R) brand is distributed in China by China Pioneer Pharma Holdings, Limited. More information about NovaBay is available here.

    Socialize and Stay Informed on NovaBay's Progress Like us on Facebook Follow us on X Connect with NovaBay on LinkedIn Visit NovaBay's Website

    Avenova Purchasing Information For NovaBay Avenova purchasing information: Please call 800-890-0329 or email sales@avenova.com Avenova.com

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240325019136/en/

    SOURCE: NovaBay Pharmaceuticals, Inc.

    <img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240325019136r1&sid=cmtx6&distro=nx&lang=en" style="width:0;height:0" />

    NovaBay Contact 
    Justin Hall
    Chief Executive Officer and General Counsel
    510-899-8800
    jhall@novabay.com 
    
    Investor Contact 
    LHA Investor Relations
    Jody Cain
    310-691-7100
    jcain@lhai.com
    

    COMTEX_449818450/1006/2024-03-25T18:38:00

    NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer...
    6:57a ET April 22 '24 BusinessWire
    NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Sto...
    6:00p ET April 19 '24 BusinessWire
    NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Re...
    6:59a ET April 17 '24 BusinessWire
    NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Fin...
    4:05p ET March 26 '24 BusinessWire
    NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Con...
    6:38p ET March 25 '24 BusinessWire
    NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor S...
    8:00a ET March 14 '24 BusinessWire
    NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophth...
    7:00a ET March 13 '24 GlobeNewswire

    Market data provided by News provided by